Market News (Page 27) - TendieTensor

Market News Page 27 of 281 • 7,014 articles

Mitsubishi HC Capital America annonce la nomination de Timothy B. Page comme nouveau président et chef de la direction

GlobeNewswire Inc. • Na

Mitsubishi HC Capital America annonce la nomination de Timothy B. Page comme nouveau président et chef de la direction

01/05/2026 05:00 PM • Mitsubishi HC Capital America has appointed Timothy B. Page as its new President and CEO effective January 1, 2026. Page, a board member with prior experience as CEO and CFO at CAI International, will lead all operations from offices in Norwalk, CT and Itasca, IL. He succeeds Craig S. Weinewuth, who will remain through March 2026 to support the transition. The appointment comes as the company implements a new strategic plan to drive growth and serve its 64,000+ clients across North America.

ALB - Gained 14.37% with multiple analysts raising price targets
MIUFY - The appointment of an experienced executive with prior CEO experience, combined with the company's implementation of a new strategic plan and emphasis on growth opportunities in the strong US-Canada economic market, signals confidence in future direction and operational continuity.

#leadership transition #CEO appointment #equipment finance #North America #strategic plan #Mitsubishi HC Capital

Mitsubishi HC Capital America Announces Timothy B. Page as New President & Chief Executive Officer

GlobeNewswire Inc. • Na

Mitsubishi HC Capital America Announces Timothy B. Page as New President & Chief Executive Officer

01/05/2026 05:00 PM • Mitsubishi HC Capital America announced the appointment of Timothy B. Page as President & Chief Executive Officer effective January 1, 2026. Page, a former CEO and CFO at sister company CAI International, will lead the company's operations as it embarks on a new strategic plan. Outgoing CEO Craig S. Weinewuth will support the transition through March 2026.

MIUFY - The appointment of an experienced executive with relevant industry background, combined with the company's strong financial position ($7 billion in assets), 64,000+ customers, and upcoming strategic initiatives indicate positive momentum and confidence in future growth.

#leadership transition #equipment financing #North America #strategic plan #CEO appointment

3 Stocks Delivered +10% Buyback Yields in 2025—What’s Next in 2026?

Investing.com • Leo Miller

3 Stocks Delivered +10% Buyback Yields in 2025—What’s Next in 2026?

01/05/2026 04:52 PM • Three S&P 500 stocks—General Motors, Southwest Airlines, and Tapestry—delivered exceptional buyback yields exceeding 10% in 2025. GM achieved a 10.8% buyback yield with $8.2 billion in repurchases and 53% stock gains. Southwest Airlines posted a 12.6% buyback yield with $2.75 billion spent, gaining 75% after opportunistic April purchases. Tapestry delivered a 10% buyback yield with $2.8 billion in buybacks and impressive 96% annual gains. However, the article cautions that buyback success depends on business quality, balance-sheet discipline, and reinvestment in core operations.

TSEM - Gained 14.39% after unveiling new foundry technology and exceeding Q4 earnings estimates
GM - Strong 10.8% LTM buyback yield with $8.2 billion in repurchases. Stock rose 53% in 2025, with significant gains following October earnings beat and guidance raise. December price targets average $85.50, suggesting 6% upside potential.

#share buybacks #buyback yield #capital returns #stock repurchases #shareholder value #market capitalization

Tyson Foods Announces First Quarter Earnings Conference Call and Webcast

GlobeNewswire Inc. • Na

Tyson Foods Announces First Quarter Earnings Conference Call and Webcast

01/05/2026 04:51 PM • Tyson Foods announced it will release its first quarter 2026 financial results on Monday, February 2, 2026, with a management conference call and webcast beginning at 9:00 a.m. Eastern Time. The company will provide a press release and supplemental materials before market open, with webcast and audio replay options available for investors.

CART - Gained 5.80% with better-than-expected Q3 results and announced significant share repurchase program
TSN - The article is a routine announcement of upcoming earnings release and conference call details. It contains no information about financial performance, guidance, or business developments that would indicate positive or negative sentiment. It is purely procedural in nature.

#earnings announcement #Q1 2026 #conference call #investor relations #financial results

TELIX URGENT CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights Before January 9th

GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

TELIX URGENT CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights Before January 9th

01/05/2026 04:51 PM • A class action lawsuit has been filed against Telix Pharmaceuticals Limited in the U.S. District Court for the Southern District of Indiana. The lawsuit alleges that defendants made false and misleading statements regarding prostate cancer therapeutic candidates, overstated supply chain quality, and misrepresented business operations and prospects during the period of February 21, 2025 to August 28, 2025. Investors have until January 9, 2026 to apply to be appointed as lead plaintiff.

AU - Gained 9.08% after reporting Q3 earnings above estimates
TLX - The company is the subject of a class action lawsuit alleging material misstatements about therapeutic progress, supply chain quality, and business operations. These allegations suggest potential fraud and have resulted in investor losses, which is significantly negative for the company's reputation and stock value.

#class action lawsuit #securities fraud #misleading statements #prostate cancer therapeutics #supply chain #investor losses #lead plaintiff deadline

NVIDIA Announces Alpamayo Family of Open-Source AI Models and Tools to Accelerate Safe, Reasoning-Based Autonomous Vehicle Development

GlobeNewswire Inc. • Nvidia Corporation

NVIDIA Announces Alpamayo Family of Open-Source AI Models and Tools to Accelerate Safe, Reasoning-Based Autonomous Vehicle Development

01/05/2026 04:49 PM • NVIDIA unveiled the Alpamayo family of open-source AI models, simulation tools, and datasets designed to advance autonomous vehicle development. The offering includes Alpamayo 1, a chain-of-thought reasoning vision language action (VLA) model with 10 billion parameters, AlpaSim simulation framework, and Physical AI Open Datasets containing 1,700+ hours of driving data. Major mobility companies including Lucid, JLR, and Uber have expressed support for the technology to accelerate level 4 autonomous vehicle deployment.

PAAS - Gained 6.15% after reporting Q3 earnings ahead of estimates
NVDA - NVIDIA is positioning itself as a leader in autonomous vehicle AI development through a comprehensive open-source ecosystem. The release of Alpamayo demonstrates technological innovation and industry leadership, with support from major automotive partners, strengthening NVIDIA's market position in the growing autonomous vehicle sector.

#autonomous vehicles #AI models #vision language action #reasoning-based AI #open-source #simulation #level 4 autonomy #physical AI #long-tail scenarios

Associated Capital Reports Estimated Fourth Quarter and Full Year Results

GlobeNewswire Inc. • Na

Associated Capital Reports Estimated Fourth Quarter and Full Year Results

01/05/2026 04:49 PM • Associated Capital Group announced a preliminary fourth quarter book value range of $44.50 to $44.70 per share, representing growth from $44.23 per share at September 30, 2025 and $42.14 per share at December 31, 2024. The company, which provides alternative investment management and direct investment services, will release detailed financial results in February.

LLY - Gained 5.06% with multiple analysts raising price forecasts
ACGP - The company reported sequential growth in book value per share from Q3 2025 ($44.23) to the preliminary Q4 2025 range ($44.50-$44.70), and significant year-over-year growth from year-end 2024 ($42.14). Additionally, the merger arbitrage strategy showed strong returns (+13.8% before expenses for the first nine months), and the company recently announced a 100% dividend increase and expanded share repurchase authorization, indicating management confidence and shareholder-friendly capital allocation.

#book value #fourth quarter results #alternative investment management #direct investment #financial services #merger arbitrage

Rogers Communications 4Q25 Investment Community Teleconference January 29, 2026 at 8:00 a.m. ET

GlobeNewswire Inc. • Na

Rogers Communications 4Q25 Investment Community Teleconference January 29, 2026 at 8:00 a.m. ET

01/05/2026 04:45 PM • Rogers Communications announced it will release its fourth quarter 2025 financial results on January 29, 2026, before market open. Management will host a teleconference at 8:00 a.m. ET to discuss results and outlook, with live webcast and telephonic access available to investors.

RCI - The article is a routine earnings announcement notification with no forward-looking statements, performance metrics, or guidance provided. It is purely procedural information about when and how to access the upcoming financial results discussion.

#financial results #Q4 2025 #earnings announcement #investor conference #teleconference

Why a $8.3 Million Cut to a 12% Yield ETF Signals a Portfolio Reset

The Motley Fool • Jonathan Ponciano

Why a $8.3 Million Cut to a 12% Yield ETF Signals a Portfolio Reset

01/05/2026 04:30 PM • Foguth Wealth Management reduced its position in the Global X NASDAQ 100 Covered Call ETF (QYLD) by 475,844 shares ($8.28 million) in Q4, signaling a strategic portfolio shift away from high-yield income plays toward broader equity exposure. The move reflects concerns that covered-call ETFs, while offering attractive 12% yields, systematically cap upside potential and underperform the S&P 500 over longer periods.

MSFT - Mentioned as a target platform for game release, with no specific positive or negative implications
QYLD - The article highlights structural limitations of the fund's covered-call strategy, which caps upside potential and trails the S&P 500 by ~7.27 percentage points. The significant institutional sell-off signals reduced confidence in the fund as a core holding, with the article noting it's better suited as a tactical allocation rather than a long-term investment.

#covered call ETF #QYLD #portfolio rebalancing #income strategy #NASDAQ-100 #yield optimization #opportunity cost #institutional investor

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025

GlobeNewswire Inc. • Na

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025

01/05/2026 04:00 PM • DBV Technologies announced positive topline results from its Phase 3 VITESSE trial evaluating VIASKIN® Peanut Patch for treating peanut allergies in children aged 4-7 years. The trial met its primary endpoints, representing a significant milestone for the company's immunotherapy treatment program.

ACHR.WS - The article suggests potential 50% stock price growth by 2026, highlighting the company's progress in developing electric vertical takeoff and landing (eVTOL) aircraft, advancing from prototypes to production, and exploring initial operational routes
DBVT - The company announced positive topline results from a Phase 3 clinical trial, which is a significant regulatory and clinical milestone. Successful Phase 3 trial outcomes typically support potential regulatory approval and commercialization prospects, representing material positive news for the company's pipeline and future revenue potential.

#VIASKIN Peanut Patch #Phase 3 trial #VITESSE #peanut allergy #immunotherapy #children aged 4-7 #positive results

Mizuho Americas Announces $1 Million in Grants Through the Mizuho USA Foundation

GlobeNewswire Inc. • Na

Mizuho Americas Announces $1 Million in Grants Through the Mizuho USA Foundation

01/05/2026 04:00 PM • Mizuho USA Foundation announced $1 million in 2025 grants focused on strengthening communities and supporting young adults in technology skills training and employment opportunities. The foundation awarded a $450,000 three-year FutureReady Grant to Pursuit for an AI training initiative, $275,000 in Opportunity Grants to eleven nonprofits, and $250,250 in Community Involvement Grants to 24 organizations. Since its formation in 2003, the foundation has awarded nearly $16 million in grants.

PRSU - Pursuit received significant funding ($450,000 over three years) for its innovative AI Build Corps for Nonprofits program, validating its social impact model and demonstrating strong organizational credibility in technology training and job placement.

#charitable grants #technology skills training #nonprofit partnerships #youth employment #AI training #community development #job placement

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. • Na

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

01/05/2026 04:00 PM • Cytokinetics' CEO Robert I. Blum is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company, a specialty cardiovascular biopharmaceutical firm, has FDA-approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy and is advancing a pipeline of cardiac muscle dysfunction treatments.

PLTR - Extremely high price-to-sales ratio of 124, suggesting potential overvaluation and market hype beyond sustainable levels
CYTK - The company has achieved FDA approval for MYQORZO and received NMPA approval in China, triggering a $7.5 million milestone payment from Sanofi. The company is presenting at a major healthcare conference and has multiple drug candidates in development, indicating strong progress in its pipeline and market expansion.

#cardiac myosin inhibitor #hypertrophic cardiomyopathy #MYQORZO #aficamten #FDA approval #heart failure #J.P. Morgan Healthcare Conference

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

GlobeNewswire Inc. • Na

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

DBVT - The company announced positive topline results from a Phase 3 clinical trial, which is a significant regulatory and clinical achievement. Meeting primary endpoints in a late-stage trial typically supports potential regulatory approval and commercialization prospects for the therapeutic candidate.

#Phase 3 trial #VIASKIN Peanut Patch #peanut allergy #immunotherapy #positive results #children #VITESSE trial

Bgin Blockchain Limited Investigated by the Portnoy Law Firm

GlobeNewswire Inc. • Portnoy Law Firm

Bgin Blockchain Limited Investigated by the Portnoy Law Firm

01/05/2026 04:00 PM • The Portnoy Law Firm has initiated an investigation into possible securities fraud at Bgin Blockchain Limited following the company's IPO in October 2025. The investigation was prompted by significant financial deterioration disclosed in November 2025, including a $96 million revenue decline, a 582.8% increase in operating expenses, and a swing from $84.8 million gross profit to a $6.3 million gross loss. Additional red flags include the termination of the Chief Communications Officer in December and an auditor change. The stock has declined 59% from its $6.00 IPO price to $2.45.

BGIN - Significant financial deterioration with $96 million revenue decline, 582.8% operating expense increase, swing from $84.8M gross profit to $6.3M gross loss, executive departure, auditor change, and 59% stock price decline from IPO price indicate serious operational and financial problems, triggering securities fraud investigation.

#securities fraud #class action #IPO #financial decline #auditor change #stock decline

Michael Burry Bets On A Venezuelan Crude Rebound: From 'Short' To 'Sour'

Benzinga • Erica Kollmann

Michael Burry Bets On A Venezuelan Crude Rebound: From 'Short' To 'Sour'

01/05/2026 03:53 PM • Renowned investor Michael Burry is betting on a Venezuelan crude oil rebound following political changes in the country. He believes Gulf Coast refineries engineered for Venezuelan heavy crude will benefit from restored supply, improving operational efficiency and margins. Burry has held Valero Energy since 2020 and plans to hold longer, while also owning Halliburton and considering additional positions. He expects U.S. contractors and oil companies to benefit from infrastructure repairs and resolution of long-standing legal claims.

VLO - Burry's primary thesis centers on Valero as the main beneficiary of Venezuelan crude supply restoration. He has held the stock since 2020 and is more resolved to hold it longer, citing improved margins from processing heavy crude that Gulf Coast refineries were purpose-built to handle.

#Venezuelan crude oil #Gulf Coast refineries #heavy sour crude #geopolitical shift #refining margins #infrastructure repair #legal claims recovery

SRS Real Estate Partners Significantly Strengthens Industrial Platform with Addition of Strategic San Diego Team

GlobeNewswire Inc. • Not Specified

SRS Real Estate Partners Significantly Strengthens Industrial Platform with Addition of Strategic San Diego Team

01/05/2026 03:52 PM • SRS Real Estate Partners announced the addition of a market-leading industrial team in San Diego, with Mike Erwin and Tucker Hohenstein joining as Executive Vice Presidents and Hank Jenkins as Vice President, all from Colliers. The team brings decades of experience in industrial, flex, and land assets, strengthening SRS's West Coast footprint and national industrial growth strategy.

CIGI - Colliers is mentioned only as the previous employer of the three professionals who joined SRS. The article does not provide information about Colliers' business performance or strategic direction, making this a neutral mention in the context of the news.

#industrial real estate #San Diego market #team expansion #commercial real estate #talent acquisition #Southern California #institutional investors

Notable Newcomers: These 2025 IPOs Dominated the Year

Investing.com • Leo Miller

Notable Newcomers: These 2025 IPOs Dominated the Year

01/05/2026 03:45 PM • In 2025, over 200 U.S. IPOs occurred, with less than a quarter beating the S&P 500's 18% return. Three standout performers were Karman (defense/aerospace, +230%), Circle Internet Group (stablecoin issuer, +150%), and Hinge Health (digital physical therapy, +45%), all significantly outperforming the broader market.

KRMN - Exceptional IPO performance with 230% return, accelerating quarterly revenue growth (42% in Q4 vs 21% in Q1), strong gross margins (41%), and analyst consensus price target suggesting 5% additional upside despite significant gains.

#IPO #2025 #stock performance #defense contractor #cryptocurrency #healthcare technology #revenue growth

How This $14 Million Bond ETF Position Signals a Clear Risk-Off Move in Late 2025

The Motley Fool • Jonathan Ponciano

How This $14 Million Bond ETF Position Signals a Clear Risk-Off Move in Late 2025

01/05/2026 03:34 PM • Northeast Planning Associates significantly increased its position in the VictoryShares Core Intermediate Bond ETF (UITB) to $13.65 million, making it the fund's second-largest holding. This move reflects a risk-off investment strategy focused on capital preservation, with the portfolio heavily weighted toward defensive assets including precious metals, short-duration Treasurys, and investment-grade bonds.

UITB - The ETF received a significant $5.8 million increase in investment from Northeast Planning Associates, elevating it to the second-largest portfolio position. The article frames this as a strategic move toward stability and capital preservation, indicating confidence in the fund's role as a core fixed income holding with strong fundamentals (AA average credit profile, 2/3 of portfolio in AAA-rated bonds).

#bond ETF #risk-off #capital preservation #intermediate-term bonds #defensive portfolio #fixed income #investment-grade bonds

Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs

The Motley Fool • Sara Appino

Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs

01/05/2026 03:33 PM • Omnicell's EVP & Chief Legal/Admin Officer Corey Manley sold 6,106 shares worth $243,629 on December 3, 2025, reducing his direct holdings by 5.85%. The sale occurred as the stock approached 52-week highs following strong Q3 results and the announcement of the company's new Titan XT automated dispensing system, which prompted analyst upgrades.

OMCL - Despite the insider sale, the overall sentiment is positive due to strong Q3 earnings that exceeded expectations, recent product launch (Titan XT system), multiple analyst upgrades, stock trading near 52-week highs, and significant recovery from May lows. The insider sale appears routine and modest relative to holdings, not indicating loss of confidence in the company.

#insider trading #medication management automation #pharmacy robotics #healthcare automation #Form 4 filing #stock sale #analyst upgrade

MCTA Investors Have Opportunity to Lead Charming Medical Limited Securities Fraud Lawsuit with the Schall Law Firm

Benzinga • Prnewswire

MCTA Investors Have Opportunity to Lead Charming Medical Limited Securities Fraud Lawsuit with the Schall Law Firm

01/05/2026 02:46 PM • The Schall Law Firm is seeking lead investors for a class action lawsuit against Charming Medical Limited (NASDAQ: MCTA) for securities fraud. The company faced an SEC trading suspension in November 2025 after its stock price spiked dramatically without justification, allegedly due to a promotion scheme involving social media advisors. Investors who purchased securities between October 21-November 12, 2025, are encouraged to join the lawsuit by February 17, 2026.

FIG - Cloud-based design platform challenging Adobe, with 45% growth in high-value customers and expected revenue CAGR of 27% from 2024 to 2027
MCTA - The company is the subject of a securities fraud lawsuit, faced an SEC trading suspension, and is alleged to have made false and misleading statements to the market. The stock price spike was allegedly driven by a promotion scheme rather than legitimate business developments, resulting in investor losses.

#securities fraud #class action lawsuit #SEC trading suspension #promotion scheme #investor losses #NASDAQ: MCTA

Charming Medical Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MCTA

Benzinga • Prnewswire

Charming Medical Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MCTA

01/05/2026 02:46 PM • The DJS Law Group announced a class action lawsuit against Charming Medical Limited (NASDAQ: MCTA) for securities law violations. The SEC suspended trading of MCTA shares following an investigation into an alleged scheme to artificially boost the company's share price through social media promotion by financial advisors. The class period covers October 21, 2025 to November 12, 2025, with a deadline of February 17, 2026 for shareholders to join the lawsuit.

INOD - Provides critical AI data preparation services for major tech companies, with expected revenue and earnings growth of 22% and 13% CAGR from 2024 to 2027
MCTA - The company faces a class action lawsuit for securities violations, SEC trading suspension, and allegations of fraudulent share price manipulation through coordinated social media promotion. These serious regulatory and legal issues pose significant risks to shareholders and the company's reputation.

#securities law violations #class action lawsuit #SEC investigation #share price manipulation #trading suspension #investor losses

smart Expands Global Reach in 2025, Set to Open New Frontiers in 2026

GlobeNewswire Inc. • Globe Newswire

smart Expands Global Reach in 2025, Set to Open New Frontiers in 2026

01/05/2026 02:00 PM • Premium EV brand smart expanded to 39 markets in 2025 by launching in 10 new countries and growing its retail network by 25% to 688 outlets. The company plans to introduce two new models (#2 and #6) in 2026 while strengthening customer services through AI-enhanced smartcare. All smart models have earned Red Dot Design Awards and 5-Star Euro NCAP Safety Ratings.

GELHY - As co-founder of the smart joint venture with Mercedes-Benz, Geely benefits from the brand's expansion to 39 markets, 25% retail network growth, and strong product recognition. The company's investment in smart is yielding positive returns through market penetration and operational success.

#electric vehicles #global expansion #market launch #premium automotive #product roadmap #retail network growth #customer services #design awards #safety ratings

Deadline Alert: Perrigo Company plc (PRGO) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. • Glancy Prongay & Murray Llp

Deadline Alert: Perrigo Company plc (PRGO) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

01/05/2026 01:49 PM • Glancy Prongay & Murray LLP is alerting Perrigo Company plc investors about a securities fraud class action lawsuit with a January 16, 2026 deadline to file as lead plaintiff. The lawsuit alleges that Perrigo made materially false statements regarding its acquisition of Nestlé's infant formula business, failing to disclose significant underinvestment, manufacturing deficiencies, and the need for substantial remediation costs exceeding initial estimates. The company's stock fell significantly on multiple occasions (15.14%, 9.8%, 11.31%, and 25.2%) as it repeatedly revised guidance downward due to infant formula business challenges.

PRGO - The company is the subject of a securities fraud lawsuit alleging material misstatements and omissions regarding its infant formula business acquisition. Multiple significant stock price declines (totaling over 60% from peak to trough during the class period), repeated downward guidance revisions, and undisclosed manufacturing and operational issues indicate serious business and legal challenges.

#securities fraud #class action lawsuit #infant formula business #Nestlé acquisition #misstatements #manufacturing deficiencies #remediation costs #guidance revision #stock decline

Deadline Alert: Alexandria Real Estate Equities, Inc. (ARE) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. • Glancy Prongay & Murray Llp

Deadline Alert: Alexandria Real Estate Equities, Inc. (ARE) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

01/05/2026 01:45 PM • Alexandria Real Estate Equities (ARE) faces a securities fraud class action lawsuit after missing Q3 2025 earnings estimates and cutting full-year guidance. The company disclosed a $323.9 million real estate impairment charge, with $206 million attributed to its Long Island City property. The stock fell 19.2% on the news. Investors have until January 26, 2026 to file a lead plaintiff motion, with allegations that the company misrepresented the value and occupancy prospects of its LIC property.

ARE - The company missed Q3 earnings estimates, cut full-year FFO guidance, disclosed a $323.9 million impairment charge, and faces a securities fraud lawsuit alleging material misstatements about its Long Island City property's value and occupancy. Stock declined 19.2% on the announcement.

#securities fraud #class action lawsuit #earnings miss #impairment charge #Long Island City #occupancy decline #stock price decline

Bioanalytical Services Market Projected to Reach US$ 11.61 Billion by 2035, Driven by Rising FDA Approvals and Clinical Trial Activity Says Astute Analytica

GlobeNewswire Inc. • Astute Analytica

Bioanalytical Services Market Projected to Reach US$ 11.61 Billion by 2035, Driven by Rising FDA Approvals and Clinical Trial Activity Says Astute Analytica

01/05/2026 01:00 PM • The global bioanalytical services market is expected to grow from US$ 3.96 billion in 2025 to US$ 11.61 billion by 2035 at a CAGR of 11.6%. Growth is driven by FDA Modernization Act 2.0 implementation, increased clinical trial activity, and a shift toward advanced testing methodologies like cell-based assays and LC-MS/MS platforms. Cell-based assays lead with 46.1% market share, while small molecules account for 55.4%. Oncology applications dominate at 32% share, driven by the explosive pipeline of 1,200+ Antibody-Drug Conjugates.

LH - Expanded Singapore bioanalytical facility to 7,300 square meters with 90 new high-skilled roles, strengthening Asia-Pacific presence

#bioanalytical services #FDA Modernization Act 2.0 #cell-based assays #LC-MS/MS #clinical trials #oncology #antibody-drug conjugates #small molecules #bioequivalence testing #contract research organizations